Insmed Incorporated Aktie News

BRIDGEWATER, N.J. , Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 92 new employees.

Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript

Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarter all in the sector.

Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.

“Big mo” stock strategies have lost their advantage, but these companies display relative strength.

— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation — — BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J. , Nov. 18, 2025 /PRNewswir...

Insmed Incorporated ( INSM ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM EST Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division Good morning, everyone. Thanks for joining the session -- fireside session was Insmed and my name is ...

More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service BRIDGEWATER, N.J. , Nov. 13, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today...